Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
REVIEW PAPER
Rheumatic diseases induced by drugs and environmental factors: the state-of-the-art – part two
Submission date: 2016-05-24
Final revision date: 2016-08-19
Acceptance date: 2016-08-23
Online publication date: 2016-10-05
Publication date: 2016-08-31
Reumatologia 2016;54(4):165-169
KEYWORDS
TOPICS
Rheumatoid arthritis- aetiology, pathogenesis, clinical features and treatmentSLE, Sjögren syndrome and APS - aetiology, pathogenesis, clinical features and treatmentScleroderma, myositis and related syndromes - aetiology, pathogenesis, clinical features and treatmentVasculitis - aetiology, pathogenesis, clinical features and treatment
ABSTRACT
The majority of rheumatic diseases belong to the group of autoimmune diseases and are associated with autoantibody production. Their etiology is not fully understood. Certain medications and environmental factors may have an influence on the occurrence of rheumatic diseases. Establishing a cause-effect relationship between a certain factor and disease induction is not always simple. It is important to administer the drug continuously or monitor exposure to a given factor in the period preceding the onset of symptoms. The lack of early diagnosed autoimmune disease, or finally the lack of symptoms within a few weeks/months after discontinuation of the drug/cessation of exposure, is also important.
The most frequently mentioned rheumatic diseases caused by drugs and environmental factors include systemic lupus erythematosus (SLE), scleroderma, systemic vasculitis, polymyositis, dermatomyositis, and Sjögren’s syndrome.
The objective of this study is to summarize current knowledge on rheumatic diseases induced by drugs and environmental factors.
The most frequently mentioned rheumatic diseases caused by drugs and environmental factors include systemic lupus erythematosus (SLE), scleroderma, systemic vasculitis, polymyositis, dermatomyositis, and Sjögren’s syndrome.
The objective of this study is to summarize current knowledge on rheumatic diseases induced by drugs and environmental factors.
REFERENCES (38)
1.
Uyar M, Elbek O, Bakır K, et al. Churg-Strauss syndrome related to montelukast. Tuberk Toraks 2012; 60: 56-58.
2.
Bukhari M. Drug-induced rheumatic diseases: a review of published case reports from the last two years. Curr Opin Rheumatol 2012; 24: 182-186.
3.
Grau RG. Drug-induced vasculitis: new insights and a changing lineup of suspects. Curr Rheumatol Rep 2015; 17: 71.
4.
D’Cruz D. Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol Lett 2000; 112-113: 421-432.
6.
Choi HK, Merkel PA, Walker AM, et al. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000; 43: 405-413.
7.
Muńoz-Grajales C, Pineda JC. Pathophysiological relationship between infections and systemic vasculitis. Autoimmune Dis 2015; 2015: 286783.
8.
D’Alessandro M, Buoncompagni A, Minoia F, et al. Cytomegalovirus-related necrotising vasculitis mimicking Henoch-Schönlein syndrome. Clin Exp Rheumatol 2014; 32 (3 Suppl 82): S73-75.
9.
Chen M, Kallenberg CG. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 2010; 9: A293-298.
10.
Kallenberg CG. Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis 2011; 70 Suppl 1: i59-63.
11.
Gómez-Puerta JA, Gedmintas L, Costenbader KH. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. Autoimmun Rev 2013; 12: 1129-1135.
12.
Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 2010; 37: 1549-1550.
13.
Liu SW, Velez NF, Lam C, et al. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol 2013; 149: 1204-1208.
14.
Hahn M, Sriharan K, McFarland MS. Gemfibrozil-induced myositis in a patient with normal renal function. Ann Pharmacother 2010; 44: 211-214.
15.
Niklas K, Niklas A, Puszczewicz M, et al. Polymyositis induced by atorvastatin. Kardiol Pol 2015; 73: 1336.
16.
Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol 2008; 59: 872-880.
17.
Yang CY, Park SA, Kim HS, et al. Polymyositis in patients taking antiviral clevudine therapy: a report of two cases. NeuroRehabilitation 2010; 26: 159-162.
18.
Sheik Ali S, Goddard AL, Luke JJ, et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 2015; 151: 195-199.
19.
Tong PL, Yu LL, Chan JJ. Drug-induced dermatomyositis after zoledronic acid. Australas J Dermatol 2012; 53: e73-75.
20.
Pignone A, Fiori G, Del Rosso A, et al. The pathogenesis of inflammatory muscle diseases: on the cutting edge among the environment, the genetic background, the immune response and the dysregulation of apoptosis. Autoimmun Rev 2002; 1: 226-232.
21.
Majewski D, Puszczewicz M, Kołczewska A. Differential diagnosis of polymyositis. Case report. Ann Acad Med Stetin 2010; 56 Suppl 1: 66-69.
22.
Takenaka K, Miyabe Y, Kasai S, et al. Polymyositis in a father and his son; a case report. Nihon Rinsho Meneki Gakkai Kaishi 2012; 35: 144-149.
23.
Darwaza A, Lamey PJ, Connell JM. Hydrallazine-induced Sjögren’s syndrome. Int J Oral Maxillofac Surg 1988; 17: 92-93.
24.
Kivity S, Arango MT, Ehrenfeld M, et al. Infection and autoimmunity in Sjogren’s syndrome: A clinical study and comprehensive review. J Autoimmun 2014; 51: 17-22.
25.
Rothschild B. Acrylamine-induced autoimmune phenomena. Clin Rheumatol 2010; 29: 999-1005.
26.
Chang K, Yang SM, Kim SH, et al. Smoking and rheumatoid arthritis. Int J Mol Sci 2014; 15: 22279-22295.
27.
Essouma M, Noubiap JJ. Is air pollution a risk factor for rheumatoid arthritis? J Inflamm (Lond) 2015; 12: 48.
28.
Badran Z, Struillou X, Verner C, et al. Periodontitis as a risk factor for systemic disease: are microparticles the missing link? Med Hypotheses 2015; 84: 555-556.
29.
Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheumatol 2014; 66: 768-769.
30.
Zandman-Goddard G, Solomon M, Rosman Z, et al. Environment and lupus-related diseases. Lupus 2012; 21: 241-250.
31.
Pellegrino P, Carnovale C, Pozzi M, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev 2014; 13: 736-741.
32.
Meyer A, Rotman-Pikielny P, Natour A, et al. Antiphospholipid syndrome following a diphtheria-tetanus vaccination: coincidence vs. causality. Isr Med Assoc J 2010; 12: 638-639.
33.
Ghattaura A, Eley KA, Molenaar E, et al. A case of extensive ulcerating vasculitis following a BCG vaccination. J Plast Reconstr Aesthet Surg 2009; 62: e286-289.
34.
Le Hello C, Cohen P, Bousser MG, et al. Suspected hepatitis B vaccination related vasculitis. J Rheumatol 1999; 26: 191-194.
35.
Stübgen JP. A review on the association between inflammatory myopathies and vaccination. Autoimmun Rev 2014; 13: 31-39.
36.
Soriano A, Afeltra A, Shoenfeld Y. Immunization with vaccines and Sjögren’s syndrome. Expert Rev Clin Immunol 2014; 10: 429-435.
37.
Shoenfeld Y, Agmon-Levin N. ‘ASIA’-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011; 36: 4-8.
38.
Parks CG, Miller FW, Pollard KM, et al. Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease. Int J Mol Sci 2014; 15: 14269-14297.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
